Retrieve available abstracts of 26 articles: HTML format
Single Articles
August 2025
UPRIMNY C, von Guggenberg E, Sviridenko A, Bayerschmidt S, et al Diagnostic Performance of the (68)Ga-Labeled Minigastrin Analog DOTA-MGS5 in
Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
J Nucl Med. 2025 Aug 28:jnumed.125.269863. doi: 10.2967/jnumed.125.269863. PubMedAbstract available
July 2025
BANG YH, Kim JH, Kim YH, Kim HR, et al Distinct Prognostic Roles of (18)F-FDG PET Metabolic Response Assessed After
Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell
Carcinoma.
J Nucl Med. 2025 Jul 3:jnumed.125.269775. doi: 10.2967/jnumed.125.269775. PubMedAbstract available
June 2025
VON HINTEN J, Viering O, Bundschuh RA, Cagliyan F, et al Feasibility of Short-Term Redifferentiation in Patients with Radioactive
Iodine-Refractory Metastatic Thyroid Cancer.
J Nucl Med. 2025 Jun 5:jnumed.125.270055. doi: 10.2967/jnumed.125.270055. PubMedAbstract available
April 2025
SHI B, Zhang Y, Wu S, Xu D, et al CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal
Carcinoma: A Proof-of-Concept Study.
J Nucl Med. 2025 Apr 30:jnumed.125.269585. doi: 10.2967/jnumed.125.269585. PubMedAbstract available
DERLIN T, Kleine-Dopke D, Neubert L, Ross TL, et al Initial Experience with Dual-Time-Point [(18)F]Flurpiridaz PET/CT for
Localization of Parathyroid Adenomas in Primary Hyperparathyroidism.
J Nucl Med. 2025 Apr 24:jnumed.124.269387. doi: 10.2967/jnumed.124.269387. PubMedAbstract available
March 2025
HAUSMANN P, Zschaeck S, Furth C, Nikulin P, et al Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving
Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma.
J Nucl Med. 2025 Mar 13:jnumed.124.268972. doi: 10.2967/jnumed.124.268972. PubMedAbstract available
February 2025
DU H, Hao X, Lin B, Tang M, et al (177)Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in
Esophageal Cancer.
J Nucl Med. 2025 Feb 6:jnumed.124.268487. doi: 10.2967/jnumed.124.268487. PubMedAbstract available
January 2025
VON GUGGENBERG E, di Santo G, Uprimny C, Bayerschmidt S, et al Safety, Biodistribution, and Radiation Dosimetry of the (68)Ga-Labeled
Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer
and Other Neuroendocrine Tumors.
J Nucl Med. 2025 Jan 16:jnumed.124.268877. doi: 10.2967/jnumed.124.268877. PubMedAbstract available
September 2024
DONG Y, Wang Z, Hu X, Sun Y, et al [(18)F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable
Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy:
A Phase II Clinical Trial.
J Nucl Med. 2024 Sep 26:jnumed.124.268557. doi: 10.2967/jnumed.124.268557. PubMedAbstract available
AL-IBRAHEEM A, Abdlkadir A, Herrmann K, Bomanji J, et al Diagnostic Accuracy of [(18)F]FDG PET/MRI in Head and Neck Squamous Cell
Carcinoma: A Systematic Review and Metaanalysis.
J Nucl Med. 2024 Sep 12:jnumed.124.268049. doi: 10.2967/jnumed.124.268049. PubMedAbstract available
WRAY R, Mauguen A, Michaud L, Leithner D, et al Development of (18)F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation
Criteria and Validation of Interreader Reliability, Reproducibility, and
Performance.
J Nucl Med. 2024 Sep 12:jnumed.124.267775. doi: 10.2967/jnumed.124.267775. PubMedAbstract available
July 2024
CLEMENT C, Leclere JC, Maheo C, Le Pennec R, et al Diagnostic Performance of (18)F-FDG PET/CT According to Delay After Treatment to
Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma.
J Nucl Med. 2024 Jul 11:jnumed.124.267391. doi: 10.2967/jnumed.124.267391. PubMedAbstract available
AL-NAQEEB G, Munger E, Ramanathan AL, Makarewicz A, et al Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary
Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy.
J Nucl Med. 2024 Jul 11:jnumed.123.266955. doi: 10.2967/jnumed.123.266955. PubMedAbstract available
April 2024
GREENSPAN BS, Hofman MS, Buscombe J The Accomplishments and Legacy of Saul Hertz, MD.
J Nucl Med. 2024;65:659-663. PubMedAbstract available
March 2024
HAIDER SP, Zeevi T, Sharaf K, Gross M, et al Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of
Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.
J Nucl Med. 2024 Mar 21:jnumed.123.266637. doi: 10.2967/jnumed.123.266637. PubMedAbstract available
CYTRYN SL, Pandit-Taskar N, Lumish MA, Maron SB, et al (18)F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in
Gastroesophageal Cancer.
J Nucl Med. 2024 Mar 21:jnumed.123.267186. doi: 10.2967/jnumed.123.267186. PubMedAbstract available
GREENSPAN BS, Hofman MS, Buscombe J Commentary on "Radioactive Iodine: A Living History".
J Nucl Med. 2024;65:495. PubMed
February 2024
LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor
Quantification and Prognosis of Cancer on PET/CT.
J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048. PubMedAbstract available
KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of
Head and Neck Cancer.
J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574. PubMedAbstract available
January 2024
GU B, Yang Z, Du X, Xu X, et al Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy
of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative
Imaging Trial.
J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556. PubMedAbstract available
ZHAO L, Pang Y, Fang J, Chen J, et al Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a
Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183. PubMedAbstract available
December 2023
VENTURA D, Dittmann M, Buther F, Schafers M, et al Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity
[(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid
Carcinoma.
J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513. PubMedAbstract available
November 2023
GUNTHER T, Holzleitner N, Viering O, Beck R, et al Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept
[(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537. PubMedAbstract available
VIERING O, Gunther T, Holzleitner N, Dierks A, et al CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using
[(68)Ga]Ga-DOTA-CCK-66.
J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380. PubMed
October 2023
LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in
Patients with Papillary Thyroid Carcinoma.
J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044. PubMedAbstract available
May 2023
MALIHA PG, Mendelsohn AH, Czernin J, Howard T, et al Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [(68)Ga]Ga-FAPI-46
PET-Positive and [(18)F]FDG PET-Negative.
J Nucl Med. 2023 May 25:265498. doi: 10.2967/jnumed.123.265498. PubMed